Even taking into consideration the high efficacy of first generation oral therapy there will to be a need for a differentiated treatment option for the 5% (+/-) that fail oral therapy. Perhaps this will be a single or dual DAA interferon-based option. Perhaps most HCV patients will never want to go back to interferon-based and stay the 12-week course. The FDA may be more open to accepting an IND for a differentiated guanosine-based nucleotide treatment option in the future for those that fail all other therapy. ACHN could potentially enter an option licensed agreement now, at little to no upfront cost, and begin making a case as a provider for these treatment failures. This may sound radical but ACHN needs to find their niche with the HCV space.
Market Data 
Markets 
AI
